These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
308 related articles for article (PubMed ID: 26059781)
1. A Prospective, Nonrandomized, Open-Label Study of the Efficacy and Safety of OnabotulinumtoxinA in Adolescents with Primary Axillary Hyperhidrosis. Glaser DA; Pariser DM; Hebert AA; Landells I; Somogyi C; Weng E; Brin MF; Beddingfield F Pediatr Dermatol; 2015; 32(5):609-17. PubMed ID: 26059781 [TBL] [Abstract][Full Text] [Related]
2. Botulinum toxin type A in the treatment of primary axillary hyperhidrosis: a 52-week multicenter double-blind, randomized, placebo-controlled study of efficacy and safety. Lowe NJ; Glaser DA; Eadie N; Daggett S; Kowalski JW; Lai PY; J Am Acad Dermatol; 2007 Apr; 56(4):604-11. PubMed ID: 17306417 [TBL] [Abstract][Full Text] [Related]
3. Botulinum toxin type a is a safe and effective treatment for axillary hyperhidrosis over 16 months: a prospective study. Naumann M; Lowe NJ; Kumar CR; Hamm H; Arch Dermatol; 2003 Jun; 139(6):731-6. PubMed ID: 12810503 [TBL] [Abstract][Full Text] [Related]
4. Treatment of hyperhidrosis with Botox (onabotulinumtoxinA): Development, insights, and impact. Lowe N; Naumann M; Eadie N Medicine (Baltimore); 2023 Jul; 102(S1):e32764. PubMed ID: 37499084 [TBL] [Abstract][Full Text] [Related]
5. Repetitive injections of botulinum toxin A continuously increase the duration of efficacy in primary axillary hyperhidrosis: a retrospective analysis in 101 patients. Brehmer F; Lockmann A; Grönemeyer LL; Kretschmer L; Schön MP; Thoms KM J Dtsch Dermatol Ges; 2015 Aug; 13(8):799-805. PubMed ID: 26176740 [TBL] [Abstract][Full Text] [Related]
6. Quality of life and social isolation in Greek adolescents with primary focal hyperhidrosis treated with botulinum toxin type A: a case series. Kouris A; Armyra K; Stefanaki C; Christodoulou C; Karimali P; Kontochristopoulos G Pediatr Dermatol; 2015; 32(2):226-30. PubMed ID: 25557249 [TBL] [Abstract][Full Text] [Related]
7. Correlation between Dermatology Life Quality Index and Minor test and differences in their levels over time in patients with axillary hyperhidrosis treated with botulinum toxin type A. Skroza N; Bernardini N; La Torre G; La Viola G; Potenza C Acta Dermatovenerol Croat; 2011; 19(1):16-20. PubMed ID: 21489361 [TBL] [Abstract][Full Text] [Related]
8. Comparison of onabotulinumtoxinA and rimabotulinumtoxinB for the treatment of axillary hyperhidrosis. An JS; Hyun Won C; Si Han J; Park HS; Seo KK Dermatol Surg; 2015 Aug; 41(8):960-7. PubMed ID: 26218729 [TBL] [Abstract][Full Text] [Related]
9. Pilot study of the safety and efficacy of Myobloc (botulinum toxin type B) for treatment of axillary hyperhidrosis. Baumann L; Slezinger A; Halem M; Vujevich J; Martin LK; Black L; Bryde J Int J Dermatol; 2005 May; 44(5):418-24. PubMed ID: 15869543 [TBL] [Abstract][Full Text] [Related]
10. Same-patient prospective comparison of Botox versus Dysport for the treatment of primary axillary hyperhidrosis and review of literature. Vergilis-Kalner IJ J Drugs Dermatol; 2011 Sep; 10(9):1013-5. PubMed ID: 22052270 [TBL] [Abstract][Full Text] [Related]
11. Dilution of botulinum toxin A in lidocaine vs. in normal saline for the treatment of primary axillary hyperhidrosis: a double-blind, randomized, comparative preliminary study. Güleç AT J Eur Acad Dermatol Venereol; 2012 Mar; 26(3):314-8. PubMed ID: 21492253 [TBL] [Abstract][Full Text] [Related]
12. Long-Term Safety and Efficacy of Botulinum Toxin A Treatment in Adolescent Patients with Axillary Bromhidrosis. Wang T; Dong J; He J Aesthetic Plast Surg; 2018 Apr; 42(2):560-564. PubMed ID: 29344685 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of methantheline bromide (Vagantin(®) ) in axillary and palmar hyperhidrosis: results from a multicenter, randomized, placebo-controlled trial. Müller C; Berensmeier A; Hamm H; Dirschka T; Reich K; Fischer T; Rzany B J Eur Acad Dermatol Venereol; 2013 Oct; 27(10):1278-84. PubMed ID: 23004926 [TBL] [Abstract][Full Text] [Related]
14. Botulinum toxin type A in the treatment of bilateral primary axillary hyperhidrosis: efficacy and duration with repeated treatments. Lowe PL; Cerdan-Sanz S; Lowe NJ Dermatol Surg; 2003 May; 29(5):545-8. PubMed ID: 12752526 [TBL] [Abstract][Full Text] [Related]
15. A 44-Week Open-Label Study Evaluating Safety and Efficacy of Topical Glycopyrronium Tosylate in Patients with Primary Axillary Hyperhidrosis. Glaser DA; Hebert AA; Nast A; Werschler WP; Green L; Mamelok RD; Quiring J; Drew J; Pariser DM Am J Clin Dermatol; 2019 Aug; 20(4):593-604. PubMed ID: 31111409 [TBL] [Abstract][Full Text] [Related]
16. Duration of Efficacy Increases with the Repetition of Botulinum Toxin A Injections in Primary Axillary Hyperhidrosis: A 15-year Study in 117 Patients. Berthin C; Maillard H Acta Derm Venereol; 2019 Dec; 99(13):1237-1240. PubMed ID: 31453629 [TBL] [Abstract][Full Text] [Related]
17. Low-dose efficacy of botulinum toxin A for axillary hyperhidrosis: a randomized, side-by-side, open-label study. Heckmann M; Plewig G; Arch Dermatol; 2005 Oct; 141(10):1255-9. PubMed ID: 16230563 [TBL] [Abstract][Full Text] [Related]
18. Botulinum toxin type A in treatment of bilateral primary axillary hyperhidrosis: randomised, parallel group, double blind, placebo controlled trial. Naumann M; Lowe NJ BMJ; 2001 Sep; 323(7313):596-9. PubMed ID: 11557704 [TBL] [Abstract][Full Text] [Related]
19. Lower relapse rate of botulinum toxin A therapy for axillary hyperhidrosis by dose increase. Karamfilov T; Konrad H; Karte K; Wollina U Arch Dermatol; 2000 Apr; 136(4):487-90. PubMed ID: 10768647 [TBL] [Abstract][Full Text] [Related]